137 related articles for article (PubMed ID: 6124330)
21. Circulatory effects of renin-angiotensin system antagonists during halothane anaesthesia in hypertensive rats.
Kaukinen S; Kataja J; Ylitalo P
Acta Anaesthesiol Scand; 1983 Feb; 27(1):81-6. PubMed ID: 6340406
[TBL] [Abstract][Full Text] [Related]
22. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and aldosterone in hypertension.
Fagard R; Lijnen P; Amery A; Reybrouck T
Contrib Nephrol; 1978; 11():175-8. PubMed ID: 699588
[TBL] [Abstract][Full Text] [Related]
23. Converting enzyme inhibition in mild and moderate essential hypertension. I. Acute effects on blood pressure, the renin-angiotensin system and blood bradykinin after a single dose of captopril.
Rasmussen S; Leth A; Ibsen H; Damkjaer Nielsen M; Nielsen F; Giese J
Acta Med Scand; 1985; 218(5):435-42. PubMed ID: 3004113
[TBL] [Abstract][Full Text] [Related]
24. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
Iimura O; Shimamoto K
Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
[TBL] [Abstract][Full Text] [Related]
25. Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension.
Matthews PG; McGrath BP; Johnston CI
Clin Sci (Lond); 1979 Dec; 57 Suppl 5():135s-138s. PubMed ID: 232017
[TBL] [Abstract][Full Text] [Related]
26. [Effect of captopril on renin-aldosterone system in essential hypertension].
Yu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 1988 Apr; 16(2):84-5. PubMed ID: 3058446
[No Abstract] [Full Text] [Related]
27. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension.
Ideishi M; Sasaguri M; Ikeda M; Arakawa K
Clin Ther; 1989; 11(4):441-51. PubMed ID: 2550133
[TBL] [Abstract][Full Text] [Related]
28. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
29. Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man.
Pettinger WA; Mitchell HC
N Engl J Med; 1975 Jun; 292(23):1214-7. PubMed ID: 236513
[TBL] [Abstract][Full Text] [Related]
30. Relationship between vasopressin and the renin-angiotensin-aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin.
Santucci A; Leonetti Luparini R; Ferri C; Ficara C; Giarrizzo C; Balsano F
J Hypertens Suppl; 1985 Nov; 3(2):S133-4. PubMed ID: 3003302
[TBL] [Abstract][Full Text] [Related]
31. [Effects of angiotensin converting enzyme inhibitor SQ 14,225 on the blood pressure, renin-angiotensin-aldosterone system and renal function in patients with malignant hypertension (author's transl)].
Shionoiri H; Uneda S; Tochikubo O; Ohonishi T; Harada J; Sesoko S; Goto E; Fujishima S; Kaneko Y
Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):13-22. PubMed ID: 6247528
[No Abstract] [Full Text] [Related]
32. Reactive hyper-reninaemia to angiotensin blockade identifies renovascular hypertension.
Case DB; Atlas SA; Laragh JH
Clin Sci (Lond); 1979 Dec; 57 Suppl 5():313s-316s. PubMed ID: 232024
[TBL] [Abstract][Full Text] [Related]
33. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
Ohman KP; Karlberg BE; Nilsson OR; Wettre S
Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.
Muiesan G; Alicandri CL; Agabiti-Rosei E; Fariello R; Beschi M; Boni E; Castellano M; Moniti E; Muiesan L; Romanelli G; Zanielli A
Am J Cardiol; 1982 Apr; 49(6):1420-4. PubMed ID: 6280474
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin converting enzyme inhibition reveals an important role for the renin system in the control of normal and high blood pressure in man.
MacGregor GA; Markandu ND; Smith SJ; Sagnella GA; Morton JJ
Clin Exp Hypertens A; 1983; 5(7-8):1367-80. PubMed ID: 6315274
[TBL] [Abstract][Full Text] [Related]
36. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients.
Ogihara T; Maruyama A; Hata T; Mikami H; Nakamaru M; Naka T; Ohde H; Kumahara Y
Clin Pharmacol Ther; 1981 Sep; 30(3):328-35. PubMed ID: 6268347
[TBL] [Abstract][Full Text] [Related]
37. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.
Atkinson AB; Cumming AM; Brown JJ; Fraser R; Leckie B; Lever AF; Morton JJ; Robertson JI
Br J Clin Pharmacol; 1982 Jun; 13(6):855-8. PubMed ID: 7046776
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic probes to identify patients with renovascular hypertension.
Sosa RE; Vaughan ED
Semin Urol; 1985 Nov; 3(4):317-24. PubMed ID: 2887024
[TBL] [Abstract][Full Text] [Related]
39. Participation of the renin-angiotensin system in the maintenance of blood pressure during changes in posture in patients with essential hypertension.
Morganti A; Sala C; Turolo L; Palermo A; Zanchetti A
J Hypertens; 1985 Feb; 3(1):55-61. PubMed ID: 2987342
[TBL] [Abstract][Full Text] [Related]
40. The renin-angiotensin system during converting enzyme inhibition with captopril in patients with severe treatment-resistant hypertension.
Rasmussen S; Damkjaer Nielsen M; Ibsen H; Leth A; Giese J
Eur J Clin Invest; 1984 Feb; 14(1):30-6. PubMed ID: 6321195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
